Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Blockade of immune checkpoints is emerging as new form of anticancer therapy. We studied the expression of PD-L1, PD-L2, PD-1 and CTLA4 mRNA expression in CD34+ cells from MDS, CMML and AML patients (N=124). Aberrant up-regulation (≥2 fold) was observed in 34%, 14%, 15% and 8% of the patients respec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Bueso-Ramos, Carlos, DiNardo, Courtney, Estecio, Marcos R, Davanlou, Masoud, Geng, Qi-Rong, Fang, Zhihong, Nguyen, Martin, Pierce, Sherry, Wei, Yue, Parmar, Simrit, Cortes, Jorge, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032802/
https://www.ncbi.nlm.nih.gov/pubmed/24270737
http://dx.doi.org/10.1038/leu.2013.355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032802/
https://www.ncbi.nlm.nih.gov/pubmed/24270737
http://dx.doi.org/10.1038/leu.2013.355

Ejemplares similares